SCHEMBL19970865

SCHEMBL19970865

O=C(c1ccc2nc(-c3cccnc3)[nH]c2c1)N1CCN(Cc2cccc(OC(F)(F)F)c2)CC1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
STAT3 P40763 1/20 0.51
ACACB O00763 1/20 0.49
JAK2 O60674 1/20 0.48
HDAC6 Q9UBN7 1/20 0.47
SLC2A1 P11166 1/20 0.47
RUNX1 Q01196 2/20 0.46
KDM4E B2RXH2 3/20 0.46
ALDH1A1 P00352 3/20 0.46
BCHE P06276 2/20 0.46
ACHE P22303 2/20 0.46
MEN1 O00255 2/20 0.45
KMT2A Q03164 2/20 0.45
LMNA P02545 1/20 0.45
MAPT P10636 1/20 0.45
RECQL P46063 1/20 0.45
ABL1 P00519 1/20 0.45
BCR P11274 1/20 0.45
KIT P10721 1/20 0.45
HTT P42858 1/20 0.44
CHEK2 O96017 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19970864 0.94 STAT3 (0.51) STAT3ACACBJAK2KDM4EALDH1A1
SCHEMBL19970859 0.92 NAMPT (0.52) STAT3ACACBHDAC6SLC2A1RUNX1
SCHEMBL19970751 0.91 BCHE (0.55) STAT3ACACBHDAC6SLC2A1RUNX1
SCHEMBL19970841 0.89 RUNX1 (0.53) SLC2A1RUNX1KDM4EALDH1A1MAPT
SCHEMBL19970858 0.86 NAMPT (0.52) STAT3ACACBJAK2RUNX1MEN1
SCHEMBL19970749 0.85 RUNX1 (0.56) STAT3ACACBRUNX1KDM4EALDH1A1
SCHEMBL19970750 0.85 MEN1 (0.53) STAT3RUNX1KDM4EALDH1A1BCHE
SCHEMBL19970737 0.85 SLC2A1 (0.57) STAT3ACACBHDAC6SLC2A1BCHE
SCHEMBL19970839 0.84 KIT (0.49) SLC2A1RUNX1KDM4EALDH1A1MAPT
SCHEMBL19970885 0.83 BCHE (0.56) ACACBHDAC6RUNX1BCHEACHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11479571-B2 Benzimidazol derivatives for treating filovirus infection CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2022-10-25 US disclosed
US-20210292350-A1 BENZIMIDAZOL DERIVATIVES FOR TREATING FILOVIRUS INFECTION UNIVERSITE D'ORLEANS (FR) 2021-09-23 US disclosed
US-20210292350-A1 BENZIMIDAZOL DERIVATIVES FOR TREATING FILOVIRUS INFECTION UNIVERSITE D'ORLEANS (FR) 2021-09-23 US disclosed
WO-2018050771-A1 BENZIMIDAZOL DERIVATIVES FOR TREATING FILOVIRUS INFECTION CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2018-03-22 WO disclosed
EP-3296297-A1 BENZIMIDAZOL DERIVATIVES FOR TREATING FILOVIRUS INFECTION CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2018-03-21 EP disclosed
EP-3296297-A1 BENZIMIDAZOL DERIVATIVES FOR TREATING FILOVIRUS INFECTION CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2018-03-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210292350-A1 BENZIMIDAZOL DERIVATIVES FOR TREATING FILOVIRUS INFECTION FIP1L1, ZC3HAV1, MAVS STAT3 2805/4885ACACB 4387/4885JAK2 2299/4885
US-11479571-B2 Benzimidazol derivatives for treating filovirus infection FIP1L1, ZC3HAV1, MAVS STAT3 2805/4885ACACB 4387/4885JAK2 2299/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.